S
Shanghai Serum Bio-Technology Co Ltd
SSE:688163
Shanghai Serum Bio-Technology Co Ltd
SSE:688163
Price:
38.25
CNY
8.36%
Market Closed
Market Cap:
¥4.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Shanghai Serum Bio-Technology Co Ltd
SSE:688163
|
CN |
|
HPC Holdings Ltd
HKEX:1742
|
SG |
Balance Sheet
Balance Sheet Decomposition
Shanghai Serum Bio-Technology Co Ltd
Shanghai Serum Bio-Technology Co Ltd
Balance Sheet Decomposition is not available for
Shanghai Serum Bio-Technology Co Ltd
Shanghai Serum Bio-Technology Co Ltd
Balance Sheet
Shanghai Serum Bio-Technology Co Ltd
Shanghai Serum Bio-Technology Co Ltd
Currency: CNY
| Dec-2013 | Dec-2014 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
13
|
11
|
93
|
132
|
118
|
116
|
516
|
151
|
182
|
|
| Cash |
0
|
11
|
93
|
132
|
118
|
116
|
516
|
151
|
182
|
|
| Cash Equivalents |
13
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
15
|
0
|
65
|
418
|
723
|
650
|
|
| Total Receivables |
16
|
19
|
27
|
20
|
8
|
16
|
9
|
23
|
38
|
|
| Accounts Receivables |
15
|
17
|
12
|
13
|
4
|
10
|
8
|
23
|
37
|
|
| Other Receivables |
1
|
2
|
15
|
6
|
4
|
6
|
1
|
0
|
1
|
|
| Inventory |
19
|
29
|
54
|
54
|
50
|
49
|
55
|
45
|
43
|
|
| Other Current Assets |
0
|
2
|
1
|
11
|
4
|
2
|
1
|
7
|
3
|
|
| Total Current Assets |
47
|
62
|
175
|
231
|
180
|
248
|
997
|
949
|
916
|
|
| PP&E Net |
69
|
65
|
66
|
84
|
78
|
105
|
117
|
128
|
160
|
|
| PP&E Gross |
0
|
0
|
66
|
84
|
78
|
105
|
117
|
128
|
160
|
|
| Accumulated Depreciation |
0
|
0
|
39
|
44
|
52
|
65
|
76
|
85
|
91
|
|
| Intangible Assets |
19
|
22
|
13
|
12
|
25
|
24
|
24
|
24
|
23
|
|
| Long-Term Investments |
0
|
0
|
20
|
29
|
23
|
20
|
17
|
17
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
16
|
10
|
7
|
6
|
10
|
11
|
12
|
|
| Total Assets |
135
N/A
|
149
+10%
|
291
+95%
|
365
+26%
|
312
-15%
|
403
+29%
|
1 166
+190%
|
1 128
-3%
|
1 120
-1%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
1
|
3
|
1
|
2
|
2
|
2
|
4
|
4
|
1
|
|
| Accrued Liabilities |
0
|
0
|
4
|
4
|
5
|
11
|
17
|
17
|
9
|
|
| Short-Term Debt |
70
|
55
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
|
| Other Current Liabilities |
8
|
28
|
26
|
19
|
8
|
2
|
4
|
4
|
9
|
|
| Total Current Liabilities |
80
|
86
|
31
|
26
|
15
|
18
|
27
|
25
|
20
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
13
|
12
|
12
|
4
|
|
| Deferred Income Tax |
0
|
0
|
3
|
3
|
3
|
3
|
6
|
5
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
80
N/A
|
86
+8%
|
34
-61%
|
28
-17%
|
18
-38%
|
33
+90%
|
45
+35%
|
43
-4%
|
25
-42%
|
|
| Equity | ||||||||||
| Common Stock |
29
|
29
|
81
|
81
|
81
|
81
|
108
|
108
|
108
|
|
| Retained Earnings |
27
|
34
|
76
|
142
|
100
|
175
|
142
|
100
|
109
|
|
| Additional Paid In Capital |
0
|
0
|
99
|
114
|
114
|
114
|
871
|
878
|
878
|
|
| Total Equity |
55
N/A
|
63
+13%
|
257
+309%
|
337
+31%
|
295
-13%
|
370
+25%
|
1 122
+203%
|
1 086
-3%
|
1 096
+1%
|
|
| Total Liabilities & Equity |
135
N/A
|
149
+10%
|
291
+95%
|
365
+26%
|
312
-15%
|
403
+29%
|
1 166
+190%
|
1 128
-3%
|
1 120
-1%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
29
|
29
|
108
|
108
|
108
|
108
|
108
|
108
|
108
|
|
Switch to:
Switch to:
See Also
Discover More
